生物科技公司MRNA周五盘中大涨5.17%,主要得益于疫苗销售前景向好。
据报道,MRNA收到了欧盟、挪威和北马其顿地区的新冠疫苗供应订单。根据协议,这17个国家未来四年内可持续采购MRNA的mRNA新冠疫苗产品,包括预充式注射器等多种形式。该公司的新冠疫苗Spikevax已在欧盟获批用于6个月及以上人群接种。
分析师认为,欧洲地区对新冠疫苗的持续需求将大幅提振MRNA销售收入。从长远看,MRNA正在利用人工智能技术拓展到个性化癌症疫苗等新领域,将为公司带来持续增长动力。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.